# EDGAR Filing Document

**Accession Number:** 0001400118
**File Stem:** 0001104659-25-077200
**Filing Date:** 2025-8
**Character Count:** 70328
**Document Hash:** 05e50f495ea40576fd5bb719d24620c2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-077200.hdr.sgml**: 20250813

**ACCESSION NUMBER**: 0001104659-25-077200

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 65

**CONFORMED PERIOD OF REPORT**: 20250813

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250813

**DATE AS OF CHANGE**: 20250813

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sagimet Biosciences Inc.
- **CENTRAL INDEX KEY:** 0001400118
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 205991472
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41742
- **FILM NUMBER:** 251209008

**BUSINESS ADDRESS:**
- **STREET 1:** 155 BOVET RD., SUITE 303
- **CITY:** SAN MATEO
- **STATE:** CA
- **ZIP:** 94402
- **BUSINESS PHONE:** (650) 561-8600

**MAIL ADDRESS:**
- **STREET 1:** 155 BOVET RD., SUITE 303
- **CITY:** SAN MATEO
- **STATE:** CA
- **ZIP:** 94402

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 3-V Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20070521

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 13, 2025**

**SAGIMET BIOSCIENCES INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41742** | **20-5991472** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**Sagimet Biosciences Inc.**

**155 Bovet Road, Suite 303, San Mateo, California 94402**

**(Address of principal executive offices, including zip code)**

**(650) 561-8600**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trade<br> Symbol(s) | Name of each exchange on which registered |
| Series A Common Stock, $0.0001 par value per share | SGMT | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition** |

---

On August 13, 2025, Sagimet Biosciences Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

On August 13, 2025, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall Exhibit 99.2 furnished herewith be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

**(d) Exhibits**

---

| | |
|:---|:---|
| Exhibit <br> No. | Document |
| [99.1](tm2523275d1_ex99-1.htm) | [Press Release of Sagimet Biosciences Inc., dated August 13, 2025.](tm2523275d1_ex99-1.htm) |
| [99.2](tm2523275d1_ex99-2.htm) | [Investor Presentation of Sagimet Biosciences Inc., dated August 13, 2025.](tm2523275d1_ex99-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Sagimet Biosciences Inc. | Sagimet Biosciences Inc. |
| Date: August 13, 2025 | By: | /s/ David Happel |
|  |  | David Happel |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2523275d1_ex99-1img001.jpg)

**Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates**

*Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China*

*Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being developed for acne in the U.S.*

*Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026*

**San Mateo, Calif., August 13, 2025** – Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended June 30, 2025, and provided recent corporate updates.

"We are making strong progress advancing our differentiated therapeutics, which are in development for the treatment of MASH and acne," said David Happel, Chief Executive Officer of Sagimet. "Following our license partner Ascletis' announcement that denifanstat met all primary and secondary endpoints in its Phase 3 clinical trial in moderate to severe acne in China, in June, we initiated a Phase 1 clinical trial of our second FASN inhibitor, TVB-3567, for development of an acne indication. Additionally, pending consultation with regulatory authorities, we plan to initiate a Phase 1 clinical trial to evaluate the PK and tolerability of a combination of our FASN inhibitor denifanstat and resmetirom in the second half of 2025 as the first step towards development of a combination product for patients living with MASH. We continue to believe in the significant therapeutic potential of FASN inhibition across multiple disease states and are pioneering the development of our FASN inhibitors to benefit underserved patients," he concluded.

**Recent Corporate Highlights**

· In
 June, the Company's license partner Ascletis Bioscience Co. Ltd. (Ascletis) reported
 that denifanstat met all primary and secondary endpoints and was generally well-tolerated
 in a Phase 3 clinical trial for the treatment of moderate to severe acne vulgaris in China.
 The randomized, double-blind, placebo-controlled, multicenter clinical trial evaluated the
 safety and efficacy of denifanstat for the treatment of patients with moderate to severe
 acne in China with 480 enrolled patients randomized 1:1 to receive denifanstat 50mg or placebo,
 once daily for 12 weeks. Ascletis reported that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o All
 primary endpoints in the Phase 3 trial were met, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the
 percentage of treatment success (defined as an Investigator's Global Assessment (IGA)
 score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from baseline) (denifanstat
 33.2% vs. placebo 14.6%, p<0.0001),

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the
 percentage change in total lesion count (denifanstat -57.4% vs. placebo -35.4%, p<0.0001)
 and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ the
 percentage change in inflammatory lesion count (denifanstat -63.5% vs. placebo -43.2%, p<0.0001).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The
 secondary endpoint of change in non-inflammatory lesion count was also met (denifanstat -51.9%
 vs. placebo -28.9%, p<0.0001).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Denifanstat
 was generally well-tolerated and, following 12 weeks of once-daily oral administration at
 50 mg, the incidence rates of treatment-emergent adverse events (TEAE) were comparable between
 denifanstat and placebo. No incidence rate of TEAEs in any category exceeded 10%.

These Phase 3 results underline the potential of FASN inhibition as a novel mechanism of action to address acne, a condition that impacts more than 50 million people in the U.S. annually, and which has seen limited innovation over the past 40 years.

· In
 June 2025, the Company initiated a first-in-human Phase 1 clinical trial of TVB-3567
 which is being developed for an acne indication in the U.S. The Phase 1 clinical trial is
 a randomized double-blind placebo-controlled trial designed to evaluate the safety, tolerability,
 PK and pharmacodynamics of TVB-3567 in healthy participants with or without acne. The trial
 is comprised of several parts including single ascending dose cohorts and multiple ascending
 dose cohorts in participants without acne, followed by testing in participants with acne
 including evaluation of pharmacodynamic biomarkers.

· The
 Company held a Key Opinion Leader (KOL) event and webcast on June 16 (<u>link here</u>)
 featuring Neal Bhatia, MD (Director of Clinical Dermatology at Therapeutics Clinical Research in San
 Diego). In the webcast, Dr. Bhatia reviewed the results of Ascletis' Phase 3 trial
 of denifanstat in moderate to severe acne and discussed the study design of our recently
 initiated Phase 1 clinical trial of TVB-3567.

· The
 Company also hosted a KOL event and webcast on May 29 (<u>link here</u>) featuring Rohit
 Loomba, MD, MHSc (Professor of Medicine, Chief, Division of Gastroenterology and Hepatology,
 and Director, MASLD Research Center, University of California San Diego), who discussed the
 potential for developing a combination of denifanstat, a fat synthesis inhibitor, with a
 fat oxidizer, such as thyroid hormone beta receptor agonist, resmetirom, to treat advanced
 metabolic dysfunction-associated steatohepatitis (MASH). The planned development program
 builds upon the successful results of the Phase 2b FASCINATE-2 clinical trial of denifanstat
 in MASH F2-F3 patients, particularly in more advanced F3 stage patients, as well as on preclinical
 data demonstrating the synergistic effect of a FASN inhibitor combined with resmetirom on
 important liver disease markers. The event also provided an overview of the planned Phase
 1 PK clinical trial of the denifanstat and resmetirom combination, and a discussion on the
 potential benefits of combination therapy to treat patients living with advanced MASH.

**Publications and Presentations**

· In
 May 2025, Sagimet presented three poster presentations featuring additional analyses
 from the Phase 2b FASCINATE-2 trial of denifanstat in MASH at the European Association for
 the Study of Liver (EASL) Congress 2025. The posters focused on antifibrotic effects of denifanstat
 in difficult-to-treat patients (<u>link here</u>), new bile acid biomarkers to measure denifanstat
 response (<u>link here</u>) and alternative endpoints to liver biopsy such as MRI to detect
 patient improvement (<u>link here</u>).

**Anticipated Upcoming Milestones**

· Sagimet
 plans to initiate a Phase 1 clinical trial to evaluate the PK and tolerability of a combination
 of denifanstat and resmetirom in the second half of 2025, with an anticipated data readout
 in the first half of 2026.

· Sagimet
 initiated a Phase 1 clinical trial of TVB-3567, for development of an acne indication. Contingent
 on discussions with regulatory authorities and the outcome of the Phase 1 trial, the Company
 anticipates starting the Phase 2 program in moderate to severe acne patients in 2026.

**Financial Results for the Three and Six Months Ended June 30, 2025**

· **Cash, cash equivalents and marketable securities** as of June 30, 2025 were $135.5 million.

· **Research and development expense** for the three and six months ended June 30, 2025, was $7.2
 million and $22.6 million, respectively, compared to $6.3 million and $11.6
 million for the three and six months ended June 30, 2024, respectively.

· **General and administrative expense** for the three and six months ended June 30,
 2025 was $4.7 million and $9.2 million, respectively, compared to $4.3
 million and $7.8 million for the three and six months ended June 30,
 2024, respectively.

· **Net loss** for the three and six months ended June 30, 2025 was $10.4
 million and $28.6 million, respectively, compared to $8.1 million and $14.7
 million for the three and six months ended June 30, 2024, respectively.

**About Sagimet Biosciences**

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S. For additional information about Sagimet, please visit <u>www.sagimet.com</u>.

**About MASH**

Metabolic-dysfunction associated steatohepatitis (MASH) is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there is only one recently approved treatment in the United States and no currently approved treatments in Europe. In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH. Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver. The goal of the name change was to establish an affirmative, non-stigmatizing name and diagnosis.

**About Acne**

There are 5.1 million acne patients treated by dermatologists annually in the U.S., and a total U.S. acne market of over 50 million people.<sup>1,2</sup> There is no cure for acne; and due to its pathology, most patients require chronic management and multiple courses of treatment for flare control annually. Additionally, adherence to topical therapies is lower than with oral agents, with an estimated 30% to 40% of patients not adhering to their topical treatments.<sup>3</sup>

1. Bickers
 DR, et al. *J Am Acad Dermatol*. 2006;55(3):490-500.

2. American
 Academy of Dermatology. Burden of Skin Disease. 2017. www.aad.org/BSD.

3. Purvis
 CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into
 the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet's clinical development plans and related anticipated development milestones, Sagimet's cash and financial resources and expected cash runway. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions.

The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet's control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates Sagimet may develop; Sagimet's ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet's relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet's estimates regarding its capital requirements; and Sagimet's ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of Sagimet's most recent filings with the Securities and Exchange Commission and available at <u>www.sec.gov</u>. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Contact:<br> Joyce Allaire <br> LifeSci Advisors

<u>JAllaire@LifeSciAdvisors.com</u>

Media Contact:

Michael Fitzhugh

LifeSci Advisors

<u>mfitzhugh@lifescicomms.com</u>

**SAGIMET BIOSCIENCES INC.**

**CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

**(unaudited)**

**(in thousands, except for share and per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Research and development | $7248 | $6313 | $22590 | $11575 |
| &nbsp;&nbsp;&nbsp;General and administrative | 4677 | 4276 | 9200 | 7782 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 11925 | 10589 | 31790 | 19357 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from operations | (11925) | (10589) | (31790) | (19357) |
| Total other income | 1539 | 2471 | 3228 | 4610 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(10386) | $(8118) | $(28562) | $(14747) |
| Net loss per share, basic and diluted | $(0.32) | $(0.25) | $(0.89) | $(0.48) |
| Weighted-average shares outstanding, basic and diluted | 32195366 | 31913887 | 32195355 | 30476657 |
| Net loss | $(10386) | $(8118) | $(28562) | $(14747) |
| Other comprehensive loss: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net unrealized loss on marketable securities | (45) | (30) | (154) | (53) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total comprehensive loss | $(10431) | $(8148) | $(28716) | $(14800) |

---

**SAGIMET BIOSCIENCES INC.**

**CONDENSED BALANCE SHEETS**

**(unaudited)**

**(in thousands)**

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30, <br> 2025** | **December 31, <br> 2024** |
| Cash, cash equivalents and marketable securities | $135466 | $158658 |
| Total assets | $137407 | $160259 |
| Current liabilties | $7247 | $4454 |
| Stockholders' equity | $130160 | $155805 |
| Liabilities and stockholders' equity | $137407 | $160259 |

---

## Exhibit 99.2

**Exhibit 99.2**

![](tm2523275d1_ex99-2img001.jpg)

Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer August 2025

![](tm2523275d1_ex99-2img002.jpg)

2 August 2025 Forward - Looking Statements and Disclaimer This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995 . All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, the presentation of data from clinical trials, Sagimet's clinical development plans and related anticipated clinical development milestones, market opportunity, competitive position and potential growth opportunities are forward - looking statements . These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward - looking statements . In some cases, you can identify forward - looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other similar expressions . The forward - looking statements in this presentation are only predictions . These forward - looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others : the clinical development and therapeutic potential of denifanstat , TVB - 3567 or any other drug candidates we may develop ; our ability to advance drug candidates into and successfully complete clinical trials , the risk the topline clinical trials may not be predictive of, and may differ from final clinical data and later - stage clinical trials ; our ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines ; that unfavorable new clinical trial data may emerge in other clinical trials of our product candidates ; that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities ; our relationship with Ascletis , and the success of its development efforts for denifanstat ; the accuracy of our estimates regarding our capital requirements ; and our ability to maintain and successfully enforce adequate intellectual property protection . These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission (SEC) and available at www . sec . gov . You should not rely on these forward - looking statements as predictions of future events . The events and circumstances reflected in our forward - looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward - looking statements . Moreover, we operate in a dynamic industry and economy . New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face . Except as required by applicable law, we do not plan to publicly update or revise any forward - looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise .

![](tm2523275d1_ex99-2img003.jpg)

3 August 2025 Leadership Team with Proven Development and Commercialization Experience Dave Happel President & CEO >20 years of experience in executive leadership in biotech and pharma Brought multiple innovative healthcare products to the market Eduardo Martins CMO >20 years of leadership of large - scale multinational clinical trials & global teams in pharma and biotech Led clinical development team of cenicriviroc for MASH Thierry Chauche CFO >20 years of financial and operational leadership experience in finance and healthcare companies Elizabeth Rozek General Counsel >20 years of legal experience including executive leadership of legal, IP and compliance functions in biopharma and biotech Rob D'Urso Senior Vice President of New Products >20 years of US and global leadership experience in dermatology Marie O'Farrell Senior Vice President of R&D >20 years of experience in R&D and translational medicine in biopharma and biotech Successfully guided development for multiple clinical programs

![](tm2523275d1_ex99-2img004.jpg)

4 August 2025 Sagimet at a Glance • Our lead molecule, denifanstat, is a novel fatty acid synthase (FASN) inhibitor with a differentiated MOA with the potential to target multiple underserved diseases • Strong clinical data demonstrates denifanstat's proof of concept across multiple disease states Unique MOA: FASN Inhibition • Denifanstat directly targets the 3 key drivers of MASH (metabolic dysfunction - associated steatohepatitis) – liver fat, inflammation, and fibrosis • Successful outcome of Phase 2b trial; met both primary endp oints with significant reduction in fibrosis • Pre - clinical data demonstrated synergistic effect of combination of FASN inhibitor and resmetirom • Phase 1 clinical trial to evaluate the pharmacokinetics ථ (PK) and tolerability of a co mbination of denifanstat and resmetirom planned to initiate in 2H 2025; data readout expected 1H 2026 Denifanstat in MASH TVB - 3567 in Acne • Our follow - on FASN inhibitor, TVB 3567, received Investigational New Drug (IND) clearance in March 2025 • First - in - human Phase 1 clinical trial initiated in June 2025 for development of an acne indication

![](tm2523275d1_ex99-2img005.jpg)

5 August 2025 Strong IP, Cash Position, and Collaboration Potential • Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in patients with moderate to severe acne vulgaris in China • Phase 3 clinical trial of denifanstat in recurrent glioblastoma multiforme (GBM) in combination with bevacizumab in progress in China • Denifanstat: • Method of use patent — 2036; potential PTE to 2041 • Composition of matter patent — 2032 • Combination of denifanstat and resmetirom: • Application filed 2024; if granted — 2044; potential PTE to 2048 • TVB - 3567: • Method of use application for TVB - 3567 for acne filed 2025; if granted — 2046 • Composition of matter patent — 2035; potential PTE to 2038 Cash Position • Nasdaq: SGMT; $135.5M cash on hand\*, expected to fund current operations through 2027 Strategic Collaboration with Ascletis in Acne & Cancer IP Portfolio \*Cash, cash equivalents and marketable securities as of 06/30/2025

![](tm2523275d1_ex99-2img006.jpg)

6 August 2025 Expected Milestone / Status Stage of Development Indication Therapeutic Area Phase 3 Phase 2 Phase 1 Preclinical Phase 2b met histology primary and multiple secondary endp oints , data announced 1Q2024 ; FDA Breakthrough Therapy designation; Phase 3 F2/F3 ready MASH Metabolic Disease Phase 1 hepatic impairment results reported 1Q 2024 Phase 1 clinical PK trial initiation planned 2H 2025 Phase 1 FIH initiated in June 2025 Acne Dermatology Phase 3 met all primary and secondary endpoints, data announced June 2025\* Identifying FASN - dependent tumor types for potential FASN inhibitor development Solid tumors Oncology Phase 3 enrollment of 120 patients achieved in 3Q2023 \* Recurrent glioblastoma (GBM) Development Pipeline: Multiple Indications and Clinical Milestones \* Trials conducted in China by Ascletis , who has licensed development and commercialization rights to all indications in Greater China Denifanstat Denifanstat TVB - 3567 Denifanstat (ASC40) TVB - 3567 Denifanstat (ASC40) Denifanstat Denifanstat/resmetirom

![](tm2523275d1_ex99-2img007.jpg)

7 August 2025 MASH • Complex disease with h eterogeneous patient population • Significant opportunity for differentiated MOA MASH: A Burgeoning Epidemic Note: MASH, or metabolic dysfunction - associated steatohepatitis, was formerly known as NASH, or nonalcoholic steatohepatitis. 1. Estes C, et al. J Hepatol. 2018;69(4):896 - 904. Estimated Patients in 20 30 1 United States 100.9 million Hepatocellular carcinoma Cirrhosis F4 25 thousand annual cases among MASLD population 3.5 million compensated and decompensated 27.0 million 10.6 million MASLD Metabolic Dysfunction - Associated Liver Disease MASH Metabolic Dysfunction - Associated Steatohepatitis MASH mod - adv F ibrosis F2 - F3

![](tm2523275d1_ex99-2img008.jpg)

8 August 2025 Sagimet's lead drug candidate, denifanstat, is a specific and potent inhibitor of FASN that functions through three independent mechanisms in MASH : FASN Inhibition Addresses Three Independent Mechanisms of MASH Development and Progression Blocking steatosis via inhibiting de novo lipogenesis in hepatocytes Reducing inflammation via preventing immune cell activation Blunting fibrosis via inhibiting stellate cell activation 1 2 3 INFLAMMATION FIBROSIS STEATOSIS Hepatocyte Kupffer cell Stellate cell CIRRHOSIS MALIGNANCY FASN FASN FASN Denifanstat

![](tm2523275d1_ex99-2img009.jpg)

9 August 2025 FASN Inhibition Directly Blocks Human Liver Stellate Cell Function Stellate cells require DNL for fibrogenesis Denifanstat blocks stellate cell activation Denifanstat directly inhibits fibrogenic activity 1 Primary human stellate cell assay Denifanstat • Stimulated by TGF - beta to activate fibrogenesis • Denifanstat showed similar inhibition to positive control ALK5 inhibitor \*p<0.05. DNL: de novo lipogenesis 1. O'Farrell M, et al. Sci Rep . 2022;12(1):15661. Sagimet Biosciences data on file. vehicle Alk5i 30 nM 100 nM 300 nM 1000 nM 0 20 40 60 Collagen / total protein (μg/mg) \* \* \* \* Denifanstat

![](tm2523275d1_ex99-2img010.jpg)

10 August 2025 Treatment Goals for MASH Across Fibrosis Staging F4 (Compensated) F3 F2 F1 MASH STAGING Risk Staging based on: • Fat • Inflammation • Fibrosis • Liver & CV Events Primary Treatment Objectives Primary Therapeutic Interventions (based on Primary Objectives) Improve Glycemic Control / Improve Dyslipidemia / Reduce Weight Resolve Steatohepatitis Prevent Progression to Cirrhosis Prevent Decompensation Metabolic & Obesity Drugs\* Metabolic\* & Anti - Fibrotic Drugs Potent Anti - Fibrotic Drugs Prevent Fibrosis Progression / Induce Fibrosis Regression LOW MEDIUM HIGH VERY HIGH Cusi K, et al. Endocr Pract . 2022;28(5):528 - 562. Rinella ME, et al. Hepatology. 2023;77(5):1797 - 1835. EASL, et al. J Hepatol. 2024;81(3):492 - 542. \*Metabolic drugs are anticipated to be background therapy for obesity and type 2 diabetes, until clinical data support use i n M ASH

![](tm2523275d1_ex99-2img011.jpg)

Strong MASH Data Creates Opportunities to Reach Advanced Patient Populations

![](tm2523275d1_ex99-2img012.jpg)

12 August 2025 FASCINATE - 2: Biopsy Trial Design Focused on Histological Endpoints AI: Artificial Intelligence, MRI - PDFF; magnetic resonance imaging derived proton density fat fraction, NAS; NAFLD Activity Score . • Biopsy confirmed F2 - F3 MASH patients (n=168) • 52 weeks, 2:1 randomization to 50mg or placebo, double - blind • Single pathology reader: Dr. Pierre Bedossa • AI digital pathology: HistoIndex Primary endpoints • NAS ≥2 points improvement w/o worsening of fibrosis • MASH resolution + NAS ≥2 improvement w/o worsening of fibrosis Selected secondary endpoints • Improvement in liver fibrosis ≥1 stage without worsening of MASH as assessed by biopsy • Digital AI pathology • MRI - PDFF: absolute decrease, % change from baseline, % pts ≥30% reduction from baseline (responders) FASCINATE - 2 Phase 2b trial design Screening Placebo Denifanstat (50 mg) 0 26 52 Study Weeks Baseline Interim Final MRI - PDFF Biomarkers Biopsy MRI - PDFF Biomarkers MRI - PDFF Biomarkers Biopsy Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100

![](tm2523275d1_ex99-2img013.jpg)

13 August 2025 FASCINATE - 2: Baseline Characteristics Were Typical of the F2/F3 MASH Population Denifanstat , n=81 Placebo, n=45 Parameter 56.1 (+/ - 10.8) 59.6 (+/ - 10.9) Age , years 48 (59%) 27 (60%) Sex , female 73 (90%) 41 (91%) Race , White 27 (33%) 15 (33%) Ethnicity , Hispanic or Latino 34.6 (+/ - 6.1) 36.5 (+/ - 6.7) BMI , kg/m 2 55 (68%) 27 (60%) Type 2 diabetes 57 (+/ - 29) 67 (+/ - 33) ALT (alanine aminotransferase) U/L 48 (+/ - 29) 52 (+/ - 27) AST (aspartate aminotransferase) U/L 16.6 (+/ - 7.1) 19.0 (+/ - 7.0) Liver Fat Content (MRI - PDFF) , % 63 (78%) 34 (76%) Baseline liver biopsy NAS ≥ 5 34 (42%) / 47 (58%) 22 (49%) / 23 (51%) Baseline liver biopsy F2/F3 38 (47%) 21 (47%) Statin (at baseline) 12 (15%) 4 (9%) GLP1 - RA (at baseline) 96 (+/ - 34) 103 (+/ - 39) LDL , mg/dL 173 (+/ - 79) 153 (+/ - 67) Triglycerides , mg/dL 9.6 (+/ - 0.8) 9.8 (+/ - 0.8) ELF (Enhanced Liver Fibrosis) Score 0.6 (0.20) 0.6 (0.19) FAST (Fibroscan AST) Score Modified intent - to - treat population (mITT) includes all patients with paired biopsies. Data are mean (SD) or n (%) Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100

![](tm2523275d1_ex99-2img014.jpg)

14 August 2025 Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100 Primary Endpoints: Liver Biopsy Cochran - Mantel - Haenszel Test – two sided at the 0.05 significance level. \* ≥1 - point improvement in ballooning or inflammation. Denifanstat Achieved Statistical Significance at Week 52 NAS ≥ 2 points improvement\* w/o worsening of fibrosis MASH resolution + NAS ≥ 2 improvement w/o worsening of fibrosis ITT population mITT population Placebo n=56 Denifanstat n=112 16% 38% Placebo n=56 Denifanstat n=112 11% 26% Placebo n=45 Denifanstat n=81 20% 52% Placebo n=45 Denifanstat n=81 13% 36% ITT population mITT population % Response % Response % Response % Response p=0.0173 p=0.0044 p=0.0003 p=0.0035

![](tm2523275d1_ex99-2img015.jpg)

15 August 2025 Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100 Secondary Endpoints: Liver Fibrosis and MASH Resolution Cochran - Mantel - Haenszel Test – Two sided at the 0.05 significance level Denifanstat Achieved Statistical Significance at Week 52 18% 41% Placebo n=45 Denifanstat n=81 % response Improvement in liver fibrosis ≥ 1 stage & no worsening of MASH at Week 52 p=0.0102 mITT population 16% 38% Placebo n=45 Denifanstat n=81 % response Resolution of MASH w/o worsening of fibrosis p=0.0043 mITT population

![](tm2523275d1_ex99-2img016.jpg)

16 August 2025 Secondary Endpoints: Liver Fibrosis \*One sided at the 0.05 significance level, \*\*Two sided at the 0.05 significance level Denifanstat Achieved Statistically Significant Improvement of Fibrosis p - value Denifanstat Placebo Subgroup Fibrosis Endpoints 0.040\*\* 30% 14% ITT > 1 stage improvement in fibrosis w/o worsening of MASH 0.0102\*\* 41% 18% mITT 0.0032\*\* 49% 13% F3 0.0065\*\* 20% 2% mITT > 2 stage improvement in fibrosis w/o worsening of MASH 0.0065\*\* 34% 4% F3 0.0386\* 5% 11% mITT Progression to cirrhosis (F4) Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100. Loomba R, et al. Presented at: EASL 2024; June 5 - 8, 2024; Milan, Italy. https://sagimet.com/wp - content/uploads/2024/06/Denifanstat_a_fatty_acid_synthase_FASN_inhibitor_shows_significant_fibrosis_impro vement_and_MASH_resolution_in_FASCINATE - 2_a_Ph2b_52_week.pdf

![](tm2523275d1_ex99-2img017.jpg)

17 August 2025 Additional Fibrosis Analysis Using AI - based Digital Pathology Digital Imaging Showed that Denifanstat Significantly Reduced Fibrosis in Advanced Patients Pre - Treatment Pt A NASH - CRN Fibrosis stage F3 Post - Treatment Pt A NASH - CRN Fibrosis stage F1 Denifanstat 0.10 - 0.30 Placebo n=45 Denifanstat n=81 LS mean change qFibrosis Continuous Value Change from Baseline p=0.0023 \*One sided at the 0.05 significance level Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100

![](tm2523275d1_ex99-2img018.jpg)

18 August 2025 qFibrosis Zonal Analysis Demonstrated that Denifanstat Improves Parameters Linked to Liver Outcomes Zone 1 Zone 2 Zone 3 Central Vein Portal Vein HA BD Response at the individual zonal parameter level was defined as "at least" 30% relative decrease from baseline. 2. Rinella M, et al. Presented at: AASLD 2024; November 15 - 19, 2023; Boston, MA. Abstract 0170. Fibrosis Improvement by Zones (Response Rate Ratio) 2 -1 0 1 2 3 4 5 6 Portal Peri-Portal Zone 2 Peri-Central Peri-CV Favors Denifanstat Favors Placebo p= 0.023 p= 0.028 Changes in periportal and portal zones have been correlated with liver outcomes and mortality by analysis of liver biopsies (n=452) from SteatoSITE study 1 1. Kendall TJ, et al. Liver Int. 2024;44(10):2511 - 2516.

![](tm2523275d1_ex99-2img019.jpg)

19 August 2025 Differentiated Mechanism of Action • In vitro data demonstrates that denifanstat reduces pro - fibrotic signaling in stellate cells , suggesting that denifanstat has the potential to remove fibrotic scar tissue and reestablish the basal extracellular matrix (ECM) scaffold even in cirrhotic (F4) patients 1 • Hepatocytes continue to be functional, and patients frequently have increased liver fat Clinical Data • PK profiles in cirrhotic (F4) patients in the Phase 1 impaired hepatic function study 3 • Positive impact on advanced fibrosis in patients in FASCINATE - 2 4 , including qF4 (quantification of fibrosis stage 4) patients based on AI - based digital pathology 5 Next Step • Potential Phase 2 proof of concept in F4 patients Denifanstat Potential in Cirrhotic (F4) Patients ~20% of Patients Progress to Cirrhosis 2 MASH MASH with fibrosis Histological features of MASH Steatosis > 5% Hepatocyte ballooning Lobular inflammation Cirrhosis 1. Kamm DR, McCommis KS. J Physiol. 2022;600(8):1825 - 1837. 2. Sheka AC, et al. JAMA. 2020;323(12):1175 - 1183 . 3. Sagimet Biosciences data on file. CLIN - 009. 4. Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100. 5. Sagimet Biosciences data on file. FASCINATE - 2 HistoIndex .

![](tm2523275d1_ex99-2img020.jpg)

20 August 2025 85% of qF4 Patients on Denifanstat Showed 1 to 2 - Stage Reductions in Fibrosis • AI may detect fibrosis regression at an earlier point in time, compared to conventional pathology • qF4 population (defined on AI platform by HistoIndex) are likely the most advanced subgroup of F3 patients in Phase 2b study (n=3) (n=3) (n=13) (n=13) Placebo qF4 at baseline Denifanstat qF4 at baseline qFibrosis continuous value qFibrosis continuous value 11/13 (85%) qF4 patients decreased by 1 or 2 qfibrosis stages measured by AI - based pathology 5/11 of qF4 patients showed > 1 stage fibrosis regression, with 4 of these being 2 - stage, measured by conventional pathology Sagimet Biosciences data on file. FASCINATE - 2 HistoIndex .

![](tm2523275d1_ex99-2img021.jpg)

21 August 2025 FASCINATE - 2: Safety Denifanstat Was Generally Well - Tolerated • No DILI (drug - induced liver injury) signal and no muscle wasting were detected, and GI (gastrointestinal) effects were comparabl e to placebo • AE of hair thinning stabilized with a 2 - to - 4 week dose pause and then reversed with down titration or study completion • Only 7% of patients discontinued from the study with treatment - related hair thinning. Hair thinning in patients receiving GLP - 1 ranges from 7% to 10% 1,2 • In two previous clinical studies of denifanstat, 2% of the patients on denifanstat experienced hair thinning at 50mg 3 Total (n=168) Denifanstat 50mg (n=112) Placebo (n=56) Event n (%) 145 (86.3) 99 (88.4) 46 (82.1) Any adverse event (AE) 71 (42.3) 51 (45.5) 20 (35.7) Adverse event related to denifanstat or placebo 16 (9·5) 13 (11.6) 3 (5.4) Serious adverse event 25 (14.9) 22 (19.6) 3 (5.4) TEAE leading to study drug discontinuation Adverse events affecting ≥ 10% of patients 25 (14.9) 19 (17.0) 6 (10.7) COVID - 19 18 (10.7) 10 (8.9) 8 (14.3) Dry eye 23 (13.7) 21 (18.8) 2 (3.6) Hair thinning 1. Wadden TA, et al. Nat Med. 2023;29(11):2909 - 2918. 2. Daniel S, et al. J Drugs Dermatol . 2025;24(4):413 - 415. 3. Sagimet Biosciences data on file. FASCINATE - 1. Phase 2a study of denifanstat in acne conducted by Ascletis in China Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100

![](tm2523275d1_ex99-2img022.jpg)

22 August 2025 Denifanstat Decreased Liver Fat by MRI - PDFF and Reduced FAST Score > 30% reduction: Cochran - Mantel - Haenszel Test. Relative reduction: Mixed - effects Model for Repeated Measures. mITT population. Two sided at the 0.05 significance level. Denifanstat Achieved Statistical Significance 21% 65% Placebo n=38 Denifanstat n=69 % response p<0.0001 MRI - PDFF ≥ 30% Relative Reduction, Week 52 FAST Change from Baseline - 0.10 - 0.10 - 0.20 - 0.30 LS mean change p<0.0001 p<0.0001 Week 26 Week 52 Placebo n=42 Denifanstat n=76 Placebo n=40 Denifanstat n=73 Mixed - effects Model for Repeated Measures – Two sided at the 0.05 significance level. mITT population. Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100. Sagimet Biosciences data on file.

![](tm2523275d1_ex99-2img023.jpg)

23 August 2025 Secondary Endpoints: Liver Enzymes Mixed - effects Model for Repeated Measures – Two sided at the 0.05 significance level. mITT population Denifanstat Decreased ALT and AST Levels ALT Percent Change from Baseline AST Percent Change from Baseline - 2.70 - 16.20 - 23.10 - 30.60 LS mean change p=0.015 p=0.030 0.00 - 12.00 - 20.60 - 26.80 LS mean change p=0.018 p=0.027 Week 26 Week 52 Week 26 Week 52 Placebo n=45 Denifanstat n=80 Placebo n=43 Denifanstat n=80 Placebo n=45 Denifanstat n=79 Placebo n=43 Denifanstat n=80 Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100. Sagimet Biosciences data on file.

![](tm2523275d1_ex99-2img024.jpg)

24 August 2025 Cardiometabolic Health mITT population. Mixed - effects Model for Repeated Measures – Two sided at the 0.05 significance level. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 . 1 For LDL - c, baseline > 100 mg/dL. Denifanstat Decreased LDL - c Levels and Increased Polyunsaturated Triglycerides LDL - c 1 Change from Baseline Saturated TG Polyunsaturated TG Week 26 Week 52 p>0.05 Mean change, mg/dL n=27 n=32 - 1.80 - 9.10 - 12.60 - 23.10 Placebo Denifanstat p>0.05 - 1.80 n=27 n=32 p>0.05 Loomba R, et al. Presented at: EASL 2024; June 5 - 8, 2024; Milan, Italy. https://sagimet.com/wp - content/uploads/2024/06/Denifanstat_a_fatty_acid_synthase_FASN_inhibitor_shows_significant_fibrosis_impro vement_and_MASH_resolution_in_FASCINATE - 2_a_Ph2b_52_week.pdf Sagimet Biosciences data on file.

![](tm2523275d1_ex99-2img025.jpg)

25 August 2025 Denifanstat Reduced De Novo Lipogenesis Two sided at the 0.05 significance level , ITT population Tripalmitin : • A saturated triglyceride which is a biomarker of DNL inhibition • Reduced by denifanstat as early as week 4 of treatment Next steps • Continue the development of tripalmitin and additional markers as potential biomarker(s) of treatment response for denifanstat Tripalmitin Change from Baseline Placebo n=52 Denifanstat n=111 Placebo n=51 Denifanstat n=107 - 2.2 LS mean change (ug/mL) - 2.4 - 0.4 - 0.1 Week 4 Week 13 p=0.001 p=0.005 Loomba R, et al. Presented at: EASL 2024; June 5 - 8, 2024; Milan, Italy. https://sagimet.com/wp - content/uploads/2024/06/Denifanstat_a_fatty_acid_synthase_FASN_inhibitor_shows_significant_fibrosis_impro vement_and_MASH_resolution_in_FASCINATE - 2_a_Ph2b_52_week.pdf Sagimet Biosciences data on file.

![](tm2523275d1_ex99-2img026.jpg)

26 August 2025 Precision Medicine: Blood Tests May Lead to Improved Patient Outcomes 1. Signature has 6 metabolites: ursodeoxycholic acid, DL - 2 - aminocaprylic acid, sarcosine, glycoursodeoxycholic acid, D(-) - 2 - aminobutyric acid, PC(0 - 18:0/22:4). Accuracy 79%, PPV 88%, NPV 63%. • MASH is a multi - faceted disease and patients may benefit from being matched with optimal treatments • Two approaches using blood tests are undergoing further evaluation • Drug response: 1 - 2 months after taking drug, tripalmitin identifies patients responding to drug treatment • P otential p redictive marker: before taking drug, signature of 6 blood metabolites enriches for responders 1 Blood test for predictive marker denifanstat denifanstat denifanstat Clinical response rate On - treatment 1 - 2 months Pre - treatment Clinical response rate Blood test for drug response (e.g. tripalmitin) Sagimet Biosciences data on file.

![](tm2523275d1_ex99-2img027.jpg)

Combination Therapy Development Program for MASH

![](tm2523275d1_ex99-2img028.jpg)

28 August 2025 Combination of FASN Inhibitor and Semaglutide Improved Histological Features in MASH Mouse Model - SMA: a marker of activated hepatic stellate cells NC VEH FASN SEMA COMBO 0 5 10 s c o r e Phenotypic Fibrosis Composite Score \* \*\* NS Fibrosis NC VEH FASN SEMA COMBO In a mouse model, combination treatment showed: 1) an additive effect on fibrosis reduction, 2) a direct impact on stellate cells, and 3) a synergistic effect on NAS reduction \* p <0.05, \*\* p<0.01, \*\*\* p<0.001, ### p<0.001 GUBRA DIO MASH mice. PSR images were analyzed by FibroNest (PharmaNest), all scores shown with parenchymal correction NS: not significant; NC: Normal chow diet control, VEH: MASH vehicle control, FASN: TVB - 3664 (FASN inhibitor), SEMA: semaglutide , COMBO: TVB - 3664/ semaglutide Tsai WW, et al. Presented at: AASLD 2023; November 10 - 14, 2023; Boston, MA. Abstract 2400 - C.

![](tm2523275d1_ex99-2img029.jpg)

29 August 2025 Patient Subset on Stable GLP1 - RA at Baseline: Liver Biopsy Cochran - Mantel - Haenszel Test – One sided at the 0.05 significance level. mITT population GLP patients were on stable dose for 6 months prior to first biopsy Denifanstat Improved MASH Resolution and Fibrosis Resolution of MASH w/o worsening of fibrosis Improvement in liver fibrosis ≥ 1 stage w/o worsening of MASH 0% 42% Placebo + GLP1 n=4 Denifanstat + GLP1 n=12 % response 0% 42% Placebo + GLP1 n=4 Denifanstat + GLP1 n=12 % response p=0.034 p=0.103 AI digital pathology results also supports fibrosis improvement in patients receiving GLP1 and denifanstat Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100. Loomba R, et al. Presented at: EASL 2024; June 5 - 8, 2024; Milan, Italy. https://sagimet.com/wp - content/uploads/2024/06/Denifanstat_a_fatty_acid_synthase_FASN_inhibitor_shows_significant_fibrosis_impro vement_and_MASH_resolution_in_FASCINATE - 2_a_Ph2b_52_week.pdf

![](tm2523275d1_ex99-2img030.jpg)

30 August 2025 Mechanism of Action Supports Combination Therapy Opportunity MOA - Mechanism of Action 1. Tsai WW, et al. Presented at: EASL 2024; June 5 - 8, 2024; Milan, Italy. https://sagimet.com/wp - content/uploads/2024/06/2024 - EASL - poster - GAN - model - final.pdf Tsai WW, et al. Presented at: EASL 2024; June 5 - 8, 2024; Milan, Italy. https://sagimet.com/wp - content/uploads/2024/06/2024 - EASL - poster - TNO - model - final.pdf Combination therapy potential: • Denifanstat MOA complementary to other MOAs – THR - beta, GLPs • Opportunity for fixed dose combinations with other oral medications Potential improved clinical outcome for patients with combination therapy of denifanstat, a fat synthesis inhibitor + a fat oxidizer (THR - beta agonist) Hypothesis: distinct and complementary mechanisms of the combination lead to synergistic effect Preclinical combination studies in mouse models showed beneficial impact of FASN inhibitor + resmetirom combination on histology and MASH biomarkers 1 Fibrosis (stellate cell) Liver fat (hepatocyte) Direct – decreases fibrogenesis in stellate cells, liver fat and lipotoxicity Direct - decreases de novo lipogenesis Denifanstat Reduces de novo Lipogenesis Indirect – decreases fibrosis due to decreased liver fat and lipotoxicity Direct - increases fatty acid oxidation and improves mitochondrial function Resmetirom Increases mitochondrial beta - oxidation FASN THR - F atty acids Metabolized Sugar Fatty acids

![](tm2523275d1_ex99-2img031.jpg)

31 August 2025 Potential Benefits of Combination Therapy in Advanced MASH Patients Note: These data are placebo - adjusted, derived from different clinical trials at different points in time, with differences in t rial design and patient populations. As a result, cross - trial comparisons cannot be made, and no head - to - head clinical trials have been conducted. 1. Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100. 2. Harrison SA, et al. N Engl J Med . 2024;390(6):497 - 509. Potential Combination Resmetirom 2 Denifanstat 1 Characteristic Potential synergies in the MOA Note: THR - beta upregulates FASN Direct – increases fatty acid oxidation Indirect – decreases fibrosis due to decreased liver fat and lipotoxicity Direct – decreases de novo lipogenesis Direct – decreases fibrogenesis in stellate cells, liver fat and lipotoxicity Mechanism Oral Oral Oral Formulation Once daily Fixed - Dose Combination (FDC) Once daily Once daily Dosing Potential synergistic effect Phase 3 data supported FDA approval for treatment of non - cirrhotic MASH Met both primary endpoints in Phase 2b trial with significant reduction in fibrosis Clinical Data A combination product could potentially offer an opportunity to serve patient groups with the strongest need of treatment, including those with stage 4 fibrosis

![](tm2523275d1_ex99-2img032.jpg)

32 August 2025 Step 1 - Phase 1 PK study for denifanstat and resmetirom • PK to evaluate any drug/drug interaction • Assess safety/tolerability • Confirm optimal combination dose levels for later clinical efficacy study in MASH Step 2 - Phase 2 clinical combination study with denifanstat and resmetirom in F4 MASH patients • At least 52 weeks combination treatment • Non - invasive biomarkers for early readout to show potential beneficial impact of the combination • Primary endpoint: liver biopsies Potential Clinical Development Program for Denifanstat and Resmetirom Combination Phase 1 plan to start in 2H 2025, subject to consultation with regulatory authorities Phase 2 study design will be informed by the results of the Phase 1 trial

![](tm2523275d1_ex99-2img033.jpg)

33 August 2025 Attractiveness of a Potential Denifanstat / Resmetirom Combination • Phase 1 clinical trial to evaluate the pharmacokinetics ථ (PK) and tolerability of a combination of denifanstat and resmetirom planned to initiate in 2H 2025; data readout expected 1H 2026 • If the outcome of this Phase 1 trial is positive, will explore moving into the development of a combination product for patients living with MASH • Prudent deployment of resources with quick path to go/no go decision Denifanstat in MASH Potential of a Fixed Dose Combination Next Steps • Denifanstat directly targets the 3 key drivers of MASH (metabolic dysfunction - associated steatohepatitis) – liver fat, inflammation, and fibrosis • Successful outcome of Phase 2b trial; met both primary endpoints with significant reduction in fibrosis 1 • Pre - clinical data demonstrated synergistic effect of combination of FASN inhibitor and resmetirom 2 • Combination of a Phase 3 - ready drug candidate, with the first drug approved for MASH • IP for the combination of denifanstat and resmetirom: • Application filed 2024; if granted — 2044; potential PTE to 2048 • Potential oral, once - daily product • Potential to address an unmet need in MASH advanced patients (F4) 1. Loomba R, et al. Lancet Gastroenterol Hepatol. 2024;9(12):1090 - 1100. 2. Tsai WW, et al. Presented at: EASL 2024; June 5 - 8, 2024; Milan, Italy. https://sagimet.com/wp - content/uploads/2024/06/2024 - EASL - poster - GAN - model - final.pdf Tsai WW, et al. Presented at: EASL 2024; June 5 - 8, 2024; Milan, Italy. https://sagimet.com/wp - content/uploads/2024/06/2024 - EASL - poster - TNO - model - final.pdf

![](tm2523275d1_ex99-2img034.jpg)

FASN Inhibition Offers Potential Benefit in Multiple Indications: Acne

![](tm2523275d1_ex99-2img035.jpg)

35 August 2025 FASN Also Plays a Key Role in Other Diseases With Significant Unmet Need FASN in cancer Supports t umor survival Enables t umor proliferation Establishes r esistance to drugs FASN in acne Increases sebum production Exacerbates sebum composition Cancer cell Membrane synthesis, intracellular signaling, protein modification Sebocyte Sebum production Palmitate Lipid building block FASN

![](tm2523275d1_ex99-2img036.jpg)

36 August 2025 Multifactorial pathogenesis of acne involves 4 key aspects: • Increased sebum in sebaceous glands (80% of lipids produced through DNL) • Abnormal or excessive follicular hyper - keratinization • Accelerated bacterial growth (C. acnes) • Localized inflammatory response Acne Pathogenesis and Potential Role of FASN Inhibitors Heng AHS, Chew FT. Sci Rep. 2020;10(1):5754. 1. O'Farrell M, et al. Sci Rep . 2022;12(1):15661. FASN Palmitate / sapienic acid Lipid synthesis Sebum production Hair Skin Surface Sebum (oil) Inflammation Sebaceous gland Skin With Acne Skin Without Acne Pimple Sebaceous gland FASN is an attractive therapeutic target for acne • Denifanstat directly reduced cutaneous (skin) sebum DNL lipids in two Phase 1 studies • FASN inhibition has potential to reduce inflammation, through decreasing cytokine secretion and Th17 activation 1

![](tm2523275d1_ex99-2img037.jpg)

37 August 2025 Blackheads Whiteheads Papules & Pustules Cysts & Nodules Acne Market Overview Global acne market is expected to reach $17B in next decade 1 5.1 million US acne patients are treated by dermatologists annually (total US acne market is 50 million people) 2,3 • Acne is the #1 or #2 patient concern in dermatology offices and 65%+ of patients in dermatology offices have private insurance 4 • Although acne treatments are currently available, d ermatologists are open to new therapies (Seysara® Tablets & Winlevi® Cream) • T here is no cure for acne ; due to its pathology, most patients require chronic management and multiple courses for flare control annually Acne patients visiting a dermatologist are aligned to potential positioning of FASN inhibitor 4 • 70 % of patients presenting to dermatologists have moderate to severe disease 4 • Approximately 70% of patients have inflammatory lesions, and 16% of patients are post - menopausal women 3 1. www.expertmarketresearch.com/reports/acne - treatment - market 2. Bickers DR, et al. J Am Acad Dermatol . 2006;55(3):490 - 500. 3. American Academy of Dermatology. Burden of skin disease. 2017. www.aad.org/BSD. 4. Sagimet Biosciences data on file. Market research conducted in July 2024 among 50 dermatologists.

![](tm2523275d1_ex99-2img038.jpg)

38 August 2025 Moderate to Severe Disease Mild Disease Acne Treatment Algorithm • Most acne patients receive skin care routines that include OTC cleansers and moisturizers to address AEs associated with their treatment Disease management involves flare and prevention intervention Treatment includes topical agents used as mono - therapy, combination therapy, or with fixed dosed combination products Main topical therapy categories • Retinoids • Benzoyl Peroxide • Antibiotics • Clascoterone • Salicylic Acid • Azelaic Acid Treatment approach adds oral products on top of the topical agents Main oral therapy categories: • Antibiotics (tetracyclines, sarecycline) • Hormonal contraceptives • Spironolactone (off - label) • Intralesional corticosteroids Severe (cystic) patients are generally managed with isotretinoin (Accutane®) Main therapy categories: • Isotretinoin Severe (Cystic) Disease

![](tm2523275d1_ex99-2img039.jpg)

39 August 2025 Clinical Data Support Mechanism of Action of a FASN Inhibitor in Acne • FASN inhibitor demonstrated a >90% reduction in sebum lipids by day 15 1,2 • FASN inhibitor maintained the reduced level of sebum lipids through the entire study 1,2 • FASN inhibitor demonstrated a dose responsive impact on sebum lipids 1,2 Note: denifanstat dose in this Phase 1 trial in cancer patients is several times higher than 50 mg dose tested in acne and MASH I n multiple Phase 1 trials, FASN inhibitor demonstrated a decrease in DNL sebum lipids 1 - 3 1. Duke G, et al. Presented at: EASL 2017; April 19 - 23, 2017; Amsterdam, The Netherlands. https://sagimet.com/wp - content/uploads/2017/05/3VBIO_EASLposter.pdf. 2. Falchook G, et al. EClinicalMedicine . 2021;34:100797. 3. Duke G, et al. Presented at: AASLD 2016; November 11 - 15, 2016; Boston, MA. https://sagimet.com/wp - content/uploads/2016/11/2016_AASLD_FASN_NASH_36x60_v10.pdf. Days on therapy (# of subjects) Phase 1 oncology trial Sebutape® assessment of cutaneous sebum lipids 1,2

![](tm2523275d1_ex99-2img040.jpg)

40 August 2025 Ascletis Acne Phase 3 Clinical Trial Design • Moderate to severe acne • Multi - center placebo controlled • 1 :1 randomization • D ouble - blind • Once daily oral dosing • 480 patients in China Primary endpoints at week 12 • % patients who receive IGA success (defined as at least a 2 - point reduction in IGA from baseline, and an IGA of 0 or 1 at week 1 2) • % change of total lesion counts from baseline • % change of inflammatory lesion counts from baseline Key secondary endpoint at week 12 • % change of non - inflammatory lesion counts from baseline Screening Placebo N=240 Denifanstat (50mg) N=240 Day 1 Week 12 Primary Efficacy Denifanstat (50mg) N=240 Safety Ph3 Double blind study 1 Ph3 Open label safety study 2 Week 12 Week 52 Denifanstat Phase 3 in acne 1. ClinicalTrials.gov. NCT06192264. Study ASC40 - 303. https://clinicaltrials.gov/study/NCT06192264. 2. ClinicalTrials.gov. NCT062 48008. Study ASC40 - 304. https://clinicaltrials.gov/study/NCT06248008.

![](tm2523275d1_ex99-2img041.jpg)

41 August 2025 Ascletis Acne Phase 3 Clinical Trial: All Primary and Secondary Endpoints Met Placebo (n=240) 50mg denifanstat (n=240) Baseline Characteristics 102.1 102.2 Total lesion count 43.1 42.1 Inflammatory lesion count 85.8 85.8 IGA=3 (moderate), % 14.2 14.2 IGA=4 (severe), % p value 50mg denifanstat (placebo adjusted) Placebo (n=240) 50mg denifanstat (n=240) Efficacy endpoints 1 <0.0001 18.6 14.6 33.2 % Treatment success [IGA] 2 (primary endpoint) <0.0001 - 22.0 - 35.4 - 57.4 % Change in total lesion count (primary endpoint) <0.0001 - 20.3 - 43.2 - 63.5 % Change in inflammatory lesion count (primary endpoint) <0.0001 - 23.0 - 28.9 - 51.9 % Change in non - inflammatory lesion count (key secondary endpoint) <0.0001 - 22.1 - 36.2 - 58.3 Absolute change in total lesion count (secondary endpoint) <0.0001 - 8.2 - 18.4 - 26.6 Absolute change in inflammatory lesion count (secondary endpoint) Baseline demographics and efficacy endpoints of 50 mg denifanstat oral, once daily for 12 weeks versus Placebo (Intent - to - treat, ITT analysis change from baseline). 1. The efficacy data are LSMEANs. 2. Treatment success is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at leas t a 2 - point decrease from baseline.

![](tm2523275d1_ex99-2img042.jpg)

42 August 2025 Ascletis Acne Phase 3 Clinical Trial Safety Data Denifanstat 50mg was generally well tolerated during the 12 - week study Treatment - emergent adverse events (TEAEs) : • TEAE incidence rates were comparable between denifanstat and placebo • No incidence rate of TEAE in any category exceeded 10% • Only two categories of TEAEs had an incidence rate of more than 5%: • Dry skin reported in 6.3% of denifanstat - treated subjects vs 2.9% in the placebo group • Dry eye reported in 5.9% of denifanstat - treated subjects vs 3.8% in the placebo group Adverse events (AEs) : • All denifanstat - related AEs were mild or moderate • No denifanstat - related grade 3 or 4 AEs • No denifanstat - related serious AEs (SAEs) • No deaths were reported

![](tm2523275d1_ex99-2img043.jpg)

43 August 2025 A double - blind, randomized, placebo - controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of TVB - 3567 in healthy and acne participants • Includes sebum analysis as pharmacodynamic readout Note: SAD = Single ascending dose. MAD = Multiple ascending dose Each SAD/MAD cohort planned to include 6 participants on active and 2 on placebo. \* Lipidomic analysis with focus on FASN - derived lipids. ClinicalTrials.gov. NCT06989840. Study SB3567 - CLIN - 001. https://clinicaltrials.gov/study/NCT06989840. Phase 1 clinical trial initiated June 2025 Second FASN Inhibitor TVB - 3567 Entered FIH Phase 1 Sebutape Sebumeter Quantity of Sebum Quality\* of Sebum PLANNED # of PARTICIPANTS DESIGN PART ~56 SAD A ~12 Food effect B ~32 MAD C ~28 MAD/ACNE D

![](tm2523275d1_ex99-2img044.jpg)

44 August 2025 Potential Clinical Development Program for TVB - 3567 in Acne Step 1 - Phase 1 first - in - human pharmacokinetic (PK) clinical trial of TVB - 3567 in healthy volunteers • PK and pharmacodynamics (PD) evaluation to confirm profile • Assess safety/tolerability • Confirm potential doses for an acne Phase 2 trial Step 2 - Phase 2 clinical trial in moderate to severe acne patients • Upon completion of Phase 1, will consult with regulatory authorities regarding Phase 2 trial design, with goal of initiating Phase 2 trial in 2026 • Phase 2 trial design will be informed by the results of the Phase 1 trial, anticipate a 12 - week dose ranging study in moderate to severe acne patients with lesion reduction, treatment success (IGA) as endpoints Phase 1 trial initiated in June 2025 Goal to initiate Phase 2 trial in 2026, subject to consultation with regulatory authorities and outcome of Phase 1 trial

![](tm2523275d1_ex99-2img045.jpg)

45 August 2025 Attractiveness of TVB - 3567 in Acne • Our second FASN inhibitor, TVB 3567, received Investigational New Drug (IND) clearance in March 2025 • First - in - human Phase 1 clinical trial of TVB 3567 initiated in June 2025 for development in acne • Upon completion of Phase 1, will consult with regulatory authorities regarding Phase 2 trial design, with goal of initiating Phase 2 in 2026 FASN Inhibitor in Acne Potential of TVB - 3567 in Acne Next Steps • Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne • Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in patients with moderate to severe acne vulgaris in China ; Denifanstat was generally well tolerated • Acne market in dermatology is large (>50m people in the US) and aligned to those patients most likely to be prescribed an oral FASN inhibitor • TVB - 3567 IP: • Method of use application for TVB - 3567 for acne filed 2025; if granted — 2046 • Composition of matter patent — 2035; potential PTE to 2038

![](tm2523275d1_ex99-2img046.jpg)

FASN Inhibition Offers Potential Benefit in Multiple Indications: Oncology

![](tm2523275d1_ex99-2img047.jpg)

47 August 2025 FASN Also Plays a Key Role in Other Diseases With Significant Unmet Need FASN in cancer Supports t umor survival Enables t umor proliferation Establishes r esistance to drugs FASN in acne Increases sebum production Exacerbates sebum composition Cancer cell Membrane synthesis, intracellular signaling, protein modification Sebocyte Sebum production Palmitate Lipid building block FASN

![](tm2523275d1_ex99-2img048.jpg)

48 August 2025 FASN Is Integral to Tumor Cell Proliferation and Surviv al KRASM – KRAS mutant. KRASWT - KRAS wild type FASN dependence • Certain cancers are dependent on DNL/FASN for proliferation especially downstream of driver oncogenes • Strategy kill tumor cells and/or avoid drug resistance by combination of FASN inhibitor with drugs that inhibit driver oncogenes Dietary fatty acids cannot compensate for de novo synthesized palmitate Specific oncogenic drivers are FASN - dependent Prevents lipid peroxidation and stress induced death Palmitate RTK e.g. MET , VEGFR Saturated fatty acids for lipid rafts and membranes Protein modification and localization/ function Receptor localization and signaling Acetyl - CoA Malonyl - CoA pS6 mTOR AKT PI3K KRAS - 4A Lipid rafts FASN Foundational Phase 1\* • 136 heavily pretreated patients received denifanstat • Recommended Phase 2 dose defined • Promising clinical activity consistent with proposed mechanism • KRASM NSCLC patients had significantly longer duration on study with denifanstat than KRASWT (p<0.02), and 91% KRASM had stable disease \* Falchook G, et al. EClinicalMedicine . 2021;34:100797.

![](tm2523275d1_ex99-2img049.jpg)

49 August 2025 GBM Prostate HCC NSCLC KRASM Cancer Program Focuses on 4 FASN - Dependent Tumor Types GBM (glioblastoma), HCC (hepatocellular carcinoma), KRASM (mutant KRAS), NSCLC (non small cell lung cancer) 1. Kelly W, et al. Clin Cancer Res. 2023;29(13):2419 - 2425. 2. ClinicalTrials.gov. NCT05118776. Study ASC40 - 301. https://clinicaltrials.gov/study/NCT05118776. 3. ClinicalTrials.gov. NCT05743621. https://clinicaltrials.gov/study/NCT05743621 . 4. Wang H, et al. Hepatology. 2022;76(4):951 - 966. 5. Liu Y, et al. Lung Cancer . 2021;153:73 - 80. 6. O'Farrell M, et al. Presented at: AARC 2016; April 16 - 20, 2016; New Orleans, LA. Abstract LB - 214. Phase 3 ongoing In China by Ascletis , denifanstat combination with bevacizumab Positive investigator sponsored Phase 2 results 1 Phase 3 enrollment of 120 patients achieved in 3Q2023 2 Status Type Phase 1 ongoing Investigator Sponsored at Weill Cornell, denifanstat combination with enzalutamide 3 Phase 1 results expected 4Q2025 Preclinical and translational work completed Patient selection strategy by bioinformatics on primary samples Positive preclinical combination results 4 Phase 2 - ready Preclinical and clinical evidence Positive preclinical combination with KRAS inhibitor 5 Encouraging monotherapy Phase 1 results with denifanstat 6 Phase 2 - ready

![](tm2523275d1_ex99-2img050.jpg)

50 August 2025 Sagimet at a Glance • Our lead molecule, denifanstat, is a novel fatty acid synthase (FASN) inhibitor with a differentiated MOA with the potential to target multiple underserved diseases • Strong clinical data demonstrates denifanstat's proof of concept across multiple disease states Unique MOA: FASN Inhibition • Denifanstat directly targets the 3 key drivers of MASH (metabolic dysfunction - associated steatohepatitis) – liver fat, inflammation, and fibrosis • Successful outcome of Phase 2b trial; met both primary endp oints with significant reduction in fibrosis • Pre - clinical data demonstrated synergistic effect of combination of FA SN inhibitor and resmetirom • Phase 1 clinical trial to evaluate the pharmacokinetics ථ (PK) and tolerability of a combi nation of denifanstat and resmetirom planned to initiate in 2H 2025; data readout expected 1H 2026 Denifanstat in MASH TVB - 3567 in Acne • Our follow - on FASN inhibitor, TVB 3567, received Investigational New Drug (IND) clearance in March 2025 • First - in - human Phase 1 clinical trial for development of an acne indication initiated in June 2025